Biotech Startups

Nat4Bio develops biotechnological solutions that preserve food using naturally-derived microorganisms, reducing food waste and chemical inputs in agriculture. The company serves food producers and supply chains aiming to extend shelf life while minimizing environmental impact.

3 investors

Nautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.

3 investors

Nava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.

3 investors

NAVAN develops a non-perturbative intracellular delivery technology that transports a wide range of cargo types into primary cell types while preserving cell viability and function. The company applies this platform to cell and gene therapy development across multiple indications through strategic partnerships.

3 investors

Navitas Life Sciences is a global clinical research partner providing clinical, regulatory, safety, and data management solutions to pharmaceutical, biotech, and federal agencies for drug development and patient safety. The company combines industry expertise with proprietary technology platforms to accelerate clinical trials and regulatory processes.

3 investors

3 investors

Nbryo develops reproductive biotechnology solutions for livestock breeding, specifically focused on cattle embryo production and assisted reproductive technologies to improve genetic outcomes and sustainability in the dairy and beef industries.

3 investors

Nectero Therapeutics develops therapeutic devices for vascular medicine, working with key opinion leaders in the field. The company operates in the medical device and biotech space.

3 investors

Nectome offers a whole-body and whole-brain human preservation method intended to retain every synapse and cell at end of life for potential future revival. The protocol is compatible with traditional funerals at room temperature and remains stable for hundreds of years when stored cold.

3 investors

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue in Phase 1 trials for MAPK-driven solid tumors, alongside a mutation-selective p53-pathway program.

3 investors

Neuroclues develops eye-tracking technology to identify neurological disorders including Parkinson's, Alzheimer's, and Multiple Sclerosis before symptoms appear, serving clinicians and healthcare practitioners. The company combines hardware, software, and cloud systems to provide biomarkers for early disease detection.

3 investors

NeuroKaire uses cellular modeling and biological measurement to help mental health providers and patients make treatment decisions for depression based on measurable biological response rather than trial-and-error approaches. The company offers diagnostic testing through CLIA-certified laboratories to provide earlier biological context for antidepressant selection.

3 investors

Axoneurotech develops neural engineering technology using a biology-first approach at the intersection of biology and engineering.

3 investors

Next Life Sciences works in reproductive healthcare, focused on solutions for couples.

3 investors

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor. Its pipeline of first-in-class immuno-oncology assets is aimed at cancer patients with B7-H7 upregulation, including those who do not respond to existing PD-1/L1 inhibitor therapies.

3 investors

Nextwave Pharma markets Quillivant XR, a prescription central nervous system stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6 and older. The product is a liquid medication taken orally and is a federally controlled substance.

3 investors

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter> <parameter name="founders">[]

3 investors

Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.

3 investors

Novel Microdevices develops a portable, battery-powered point-of-care molecular diagnostic system that runs PCR-based nucleic acid amplification on disposable cartridges to detect pathogens and antibiotic-resistance mutations in about 15 minutes. The system targets same-visit testing and diagnosis, with an emphasis on low-resource settings and low- and middle-income countries.

3 investors

Novellus operates a technology platform for securities lending that lets institutional participants transact directly on a principal-to-principal basis, covering the full lifecycle including settlement and collateralization. It targets institutional market participants looking to in-source securities lending workflows.

3 investors

Novogaia develops novel medicines derived from fungi by using machine learning to identify drug-like molecular structures from natural samples and match them to targets addressing unmet medical needs.

3 investors

Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T). The company focuses on treatments for rare and debilitating diseases.

3 investors

Novotech is a contract research organization (CRO) that provides clinical trial execution and scientific advisory services for biotech and biopharma sponsors, including complex cell and gene therapy trials. It has a strong regional focus on the Asia-Pacific market.

3 investors

NOWDiagnostics develops rapid, point-of-care and consumer diagnostic tests. The company operates in the medical diagnostics and MedTech industry.

3 investors